ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 304

Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance

Doquyen H. Huynh1, Carol Etzel2, Vanessa Cox3, J. M. Kremer4, Jeffrey D. Greenberg5 and Arthur Kavanaugh6, 1Rheumatology, UC San Diego School of Medicine, San Diego, CA, 2CORRONA, Inc, Southborough, MA, 3General Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, 6University of California San Diego, San Diego, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Anti-citrullinated protein antibodies (ACPA) have been considered a relatively specific marker for rheumatoid arthritis (RA), and may play a role in its pathogenesis. In recent years, it has been shown that ACPA can be found at a greater prevalence among psoriatic arthritis (PsA) patients  (approximately 8% or more) than in the general population.  Also, ACPA have been isolated from the synovial fluid of PsA patients.  Several small anecdotal reports have suggested that PsA patients with positive ACPA may have greater swollen/tender joint counts with more deformities and radiologic changes than ACPA negative PsA patients; however, other studies have suggested no difference.  The present study evaluated whether clinical features differ between PsA patients who are ACPA (+) from those who are ACPA (-).  

Methods: A cross sectional study of patients with physician diagnosed PsA in the CORRONA database, a large national registry of patients with RA and PsA.  ACPA was performed in local labs. ACPA (+) and ACPA (-) PsA patients were evaluated for differences in disease activity, disease severity and immunomodulatory medication use.  Evaluations included: tender joint count, swollen joint count, HAQ, patient global assessment, physician global assessment, DAS 28, CDAI, presence of enthesitis, presence of dactylitis, skin psoriasis activity, presence of Sjogrens symptoms, and radiographic changes (defined by presence or absence of erosions, joint space narrowing and joint deformity).  ACPA (+) and ACPA (-) groups were also assessed for smoking status and the presence of rheumatoid factor (RF) and repeat analysis was done to determine if RF presence contributed to any differences. 

Results: Through 2012, there were 5,363 PsA patients  in the CORRONA database,  17.7% of whom had test results for ACPA: 842 were ACPA (-) and 116 ACPA (+).  There was no significant differences in any measures of disease activity or disease severity (including radiographic changes) or the use of immunomodulatory medications between ACPA (+) and ACPA(-) patients.  Interestingly, ACPA (+) patients had a lower average tender joint count (a mean difference of -0.89; 95% CI -1.78, -0.02).  Further stratification into subgroups based upon the presence of RF did not reveal any clinically important differences with the exception of ACPA (+)/RF (-) group who had a higher swollen joint count (a mean SJC of 4.57, p 0.003).  There was also no difference in smoking status amongst ACPA (+) and ACPA (-) PsA patients.

Conclusion: In a large cohort of PsA patients in clinical practice, there were no differences in disease activity, disease severity (including radiographic changes) or the use of immunomodulatory medications between ACPA (+) and ACPA (-) PsA patients. The data suggest that different than for RA, the presence of ACPA(+) may represent only an epiphenomenon in PsA. The fine specifities of ACPA in PsA patients have not yet been defined.


Disclosure:

D. H. Huynh,
None;

C. Etzel,

Corrona Inc.,

3;

V. Cox,

Corrona, Inc.,

3;

J. M. Kremer,

AZ, Genentech, Lilly, Pfizer, AZ,

2,

AZ, Genentech, Lilly, Pfizer, AZ,

5;

J. D. Greenberg,
None;

A. Kavanaugh,

AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB,

2,

AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-protein-antibodies-in-patients-with-psoriatic-arthritis-clinical-relevance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.